



President's Message

Dear Colleagues:

Happy New Year! I hope everyone had a great holiday season and was able to get some time off to refresh before the cold winter months.

I am hoping that you will all consider coming to the CAMO Annual Scientific Meeting, which is MOVING to MaRS. The meeting will be chaired by Drs. Samantha Gray and Lacey Pitre be held on May 2nd. The theme is *In Search of the Best Support*. The topics include technology and social media, an expert panel talking about toxicities of the immune-oncology drugs and an update on thrombosis in malignancy. We are keeping the format of last year with the oral presentations in the morning and rapid lightning presentation in the afternoon for our abstracts.

At the annual general meeting I will update you on some of the things that have happened since we last meet and we will be looking for volunteers to help run several committees that we have created.

The evening before, OncologyEducation is hosting a symposium on *What is the Future of Technology in Cancer Care?* On Thursday night during the CAMO awards dinner, Dr. Elizabeth Eisenhauer will be awarded the 2019 Pioneer in Canadian Oncology and be presenting the pioneer lecture. Lastly CAMO in conjunction with WinC is sponsoring a dinner Friday night on *Oncologist Professional and Personal Well-Being*.

The fellowship committee awarded Dr. Lawson Eng the 2019 CAMO fellowship titled *Acute care use and outcomes of immune-related adverse events (irAEs) during immunotherapy*. This was generously sponsored by Roche, Platinum level and Pfizer Gold level.

On behalf of the entire Executive, I am hoping you'll be able to join us for both the Annual Scientific Meeting as well as the Awards dinner that evening. It will be nice to see you all at the meeting for the learning but also to catch up.

I am looking forward to seeing you at the meeting!

Bruce Colwell, MD FRCP(C)
CAMO President

Inside this issue:

Annual Meeting Update | p.3-4

Meet the Executive | p.5

CanREValue Project | p.6-7

Important Dates | p.8



Message du président

Chers collègues,

Bonne année 2019! J'espère que vous avez passé une belle période des fêtes et que vous avez réussi à prendre un congé pour refaire le plein d'énergie avant le froid hivernal.

J'espère aussi que vous songerez tous à assister à la Réunion annuelle scientifique de l'ACOM, qui se dirige vers MaRS. La réunion du 2 mai, présidée par les Dres Samantha Gray et Lacey Pitre, aura pour thème « *À la recherche du meilleur soutien* ». Parmi les sujets abordés figurent la technologie et les médias sociaux, un groupe d'experts qui traiteront de la toxicité des médicaments immuno-oncologiques, ainsi qu'une mise à jour sur la thrombose associée à une tumeur maligne. Nous conservons le format de l'an dernier : les présentations orales auront lieu en matinée, suivies d'une présentation éclair des résumés en après-midi.

Lors de la Réunion générale annuelle je vous informerai de certains développements depuis notre dernière réunion. Entre autres, nous sommes à la recherche de bénévoles pour diriger plusieurs comités que nous avons créés.

La veille de la réunion, OncologyEducation présente un symposium ayant pour thème *What is the Future of Technology in Cancer Care? (Quel est l'avenir de la technologie dans le domaine des soins de cancérologie?)* Le jeudi en soirée, durant le souper de remise des prix de l'ACOM, la Dre Elizabeth Eisenhauer sera nommée « Pionnière de l'oncologie au Canada 2019 » et elle présentera la Conférence des pionniers. Enfin, en collaboration avec WinC, l'ACOM commandite un souper le vendredi soir portant sur le *bien-être personnel et professionnel des oncologues*.

Le Comité des bourses a décerné la bourse de recherche 2019 de l'ACOM au Dr Lawson Eng pour son projet intitulé *Acute care use and outcomes of immune-related adverse events (irAEs) during immunotherapy*. La bourse est généreusement commanditée par Roche, niveau Platine, et Pfizer, niveau Or.

Au nom de tous les membres du Comité directeur, j'espère que vous serez des nôtres pour la Réunion annuelle scientifique et le souper de remise des prix en soirée. Il sera bon de se revoir à la réunion pour les apprentissages qu'elle facilitera et pour se rattraper dans nos nouvelles.

Bruce Colwell MD FRCP(C)
Président de l'ACOM

HIGHLIGHTS

CAMO 2019 Annual Scientific Meeting



The CAMO Annual Scientific Meeting will take place on **Thursday, May 2, 2019** in Toronto, ON at **The MaRS Centre**.



PRELIMINARY PROGRAM

Wednesday May 1 2019

[CAMO 2019 Evening Symposium: What is the Future of Technology in Cancer Care?](#)

Hosted by OncologyEducation

1730-2045 @ the Chelsea Hotel

Thursday May 2 2019

[CAMO 2019 Annual Scientific Meeting](#)

0700-1700 @ the MaRS Centre

Many great topics will be presented and the speakers are high-calibre. From technology & social media to a panel discussion on immuno-oncology cases and an update on thrombosis in malignancy.

**“IN SEARCH
OF THE BEST
SUPPORT”**

[CAMO 2019 Pioneer Lecture Presentation & Awards Dinner](#)

1830-2200 @ The Ontario Heritage Centre

Come meet your fellow colleagues from across the country and listen to Dr. Elizabeth Eisenhauer, CAMO 2019 CAMO Pioneer Award recipient.

Friday May 3 2019

[The Woman in Cancer & All in Cancer in conjunction with CAMO: Oncologist Professional and Personal Well-Being by Dr. Mamta Gautam](#)

1830-2100 @ the Bangkok Garden Restaurant

CLICK HERE to download the preliminary program.



REGISTRATION IS NOW OPEN!

Don't delay, register today! Early bird registration deadline is March 14, 2019.

[CLICK HERE](#) to register and take advantage of great prices!



ACCOMMODATION

All registrants are required to make their own accommodation arrangements directly with **The Courtyard Toronto Downtown Hotel** as soon as possible. A special room rate is available (\$239.00 standard/standard two beds per night). Cut off date for reservation is April 10, 2019.

[CLICK HERE](#) to reserve your hotel room today!

**NEW – CLAIM SECTION 3 CME CREDITS...
MORE INFORMATION TO COME!**

CAMO EXECUTIVE

PRESIDENT

Dr. Bruce Colwell



VICE PRESIDENT

Dr. Desiree Hao



SECRETARY TREASURER

Dr. Sharlene Gill



PAST PRESIDENT

Dr. Hal Hirte



EXECUTIVE DIRECTOR

Ms. Alexi Campbell



“ The Canadian Association of Medical Oncologists, a national specialty society of the Royal College of Physicians and Surgeons of Canada, will contribute to cancer control, through research, education, and clinical practice in prevention, screening, diagnosis, treatment, supportive care, palliative care and rehabilitation.



CanREValue Project

Value-based decisions from Real World Evidence

Introducing the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Project

In 2017, a group of Canadian investigators, led by Dr Kelvin Chan received funding from CIHR's Partnership for Health Systems Improvement initiative for a grant for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) project. This project will develop a framework for the generation and use of Real-World Evidence (RWE) for cancer drug funding decisions.

What are the potential benefits of CanREValue for medical oncologists and other stakeholders?

The development of a framework for the generation and use of RWE is expected to improve system resource allocation and support system sustainability. The incorporation of RWE into cancer drug funding decisions can support:

- I. Evidence-based reassessment of recommendations on cancer drugs made by Canadian HTA organization (e.g. CADTH¹, INESSS², and provincial HTA organizations)
- II. Reconsideration of prior funding decisions, including the potential for refined clinical criteria, renegotiation of price, or reinvestment

In addition, incorporation of RWE into cancer drug decision-making could:

- i. Increase understanding of the clinical effectiveness and safety of new or previously funded cancer drugs
- ii. Advance understanding of how new cancer drugs work in the real world, particularly in patients who were not included in clinical trials by virtue of age, co-morbidities and prior therapies

...2

The CanREValue Project Team and Working Groups

The CanREValue project brings together key stakeholders including the Canadian Agency for Drugs and Technologies in Health; Institut national d'excellence en santé et en services sociaux; Canadian Centre for Applied Research in Cancer Control; pan-Canadian Oncology Drug Review; Canadian Association of Provincial Cancer Agencies; the pan-Canadian Pharmaceutical Alliance, Health Canada, Ministries and departments of Health, and provincial cancer agencies from across Canada. By providing a platform for stakeholders to discuss their needs and existing evidence gaps, CanREValue will enable knowledge exchange, address policy relevant research questions and develop a framework for the generation and use of RWE that will be relevant and useful to decision/policy-makers and payers.

Five Working Groups (WGs) have been established consisting of key stakeholders and experts to develop the framework. The different WGs are i) Planning and Drug Selection ii) Methods iii) Data iv) Reassessment and Uptake; and v) Engagement.

Project process & Key Deliverables

The key deliverables of each WG are:

- Planning and Drug Selection WG – recommend a selection process and criteria for prioritizing RWE evaluations
- Data WG – recommend the strategies to identify, access and harmonize the data elements required to undertake RWE projects in each province
- Methods WG – recommend the most appropriate statistical methods to conduct robust RWE evaluations
- Reassessment and Uptake WG – recommend on a reassessment process and strategies for incorporating RWE results into policy decisions
- Engagement WG – ensure that all key stakeholders, including industry, clinicians, patients are given voice in the development and implementation of the framework

In conclusion, CanREValue is a multi-stakeholder initiative to provide recommendation- and decision-makers with advice on a framework for the conduct and use of RWE for oncology drugs. The CanREValue team will develop a framework to facilitate the generation and use of RWE for cancer drug funding decisions in Canada. Our integrated knowledge translation strategy will ensure that all stakeholders, including patients and the public, will have had opportunity to provide input into the development of the framework and access to our final recommendations. Medical oncologists as the prescribers of oncology products should be aware of the initiative and avail themselves of opportunities to shape the recommendations by providing input to surveys or through other opportunities as they present themselves. If you have questions in the interim, please contact Dr. Bill Evans, the chair of the Engagement Working Group, at billevans@cogeco.ca for further information.



Canadian Lung Conference

February 7-8, 2019 | Vancouver, BC

Neurological Disorders & Stroke

March 14-16, 2019 | Toronto, ON

**Adolescent & Young Adult Survivorship
Symposium: A New Vision**

March 20, 2019 | Toronto, ON

CAMO ASM 2019

May 1-3, 2019 | Toronto, ON

CCTG Spring Meeting

May 3-5, 2019 | Toronto, ON

ASCO

May 31 to June 4, 2019 | Chicago, IL

ESMO 2019 Congress

Sept 27 to Oct 1, 2019 | Barcelona, Spain

CSIM 2019 Annual Meeting

October 2-5, 2019 | Halifax, NS

CAMO CONTACT INFORMATION

Canadian Association of Medical Oncologists

1309 Carling Ave

PO Box 35164 Westgate

Ottawa, ON K1Z 1A2

Tel: 613.415.6033

Email: info@camo-acom.ca

www.camo-acom.ca

Ms. Alexi Campbell

Executive Director

